Untitled

Motoo, Yoshiharu; Satomura, Yoshitake; Mouri, Ikurou; Mouri, Hisatsugu; Ohtsubo, Koushiro; Sakai, Junta; T, Fujii; Taga, Hiromi; Yamaguchi, Yasushi; Watanabe, Hiroyuki; Okai, Takashi; Sawabu, Norio

doi:10.1023/a:1026620006078

Cited by 18 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same experiment was performed with MIA PaCa-2 cells, which were incubated with labeled THP1-EVs for 2 h. REG3β concentrations used in this experiment were within the range of plasma REG3β levels reported in pancreatic cancer patients 32 . The concentration of EVs was selected according to previous in vitro studies 33, 34 .…”

Section: Methodsmentioning

confidence: 62%

REG3β modifies cell tumor function by impairing extracellular vesicle uptake

Bonjoch

Gironella

Iovanna

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Extracellular vesicles (EVs), including exosomes and microvesicles, are nano-sized membrane vesicles containing proteins and nucleic acids, which act as intercellular messengers. They play an important role in a variety of physiological processes, as well as in pathological situations such as inflammation or cancer. Here, we show that in the case of pancreatic ductal adenocarcinoma (PDAC), the healthy pancreatic tissue surrounding the tumor releases REG3β, a lectin that binds to the glycoproteins present in the surface of EVs, thus interfering with their uptake and internalization by target cells. In vitro, the disruption of the signaling mediated by EVs due to the presence of REG3β, prevents the EV-induced phenotypic switch in macrophages, inhibits the increased cell migration of cancer cells and reverses a number of metabolomic changes promoted by EVs. In vivo, the uptake of REG3β+ EVs by tumor cells is significantly impaired. Furthermore, it results in an increase of circulating REG3β+ EVs in blood of pancreatic cancer patients. Our findings highlight the effect of a lectin released by the healthy pancreatic tissue surrounding the tumor in modulating the EV-mediated interactions between different cell types in PDAC.

show abstract

Section: Methodsmentioning

confidence: 62%

REG3β modifies cell tumor function by impairing extracellular vesicle uptake

Bonjoch

Gironella

Iovanna

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…It is a secretory protein produced by pancreatic acinar cells and intestinal Paneth cells but its function is not clear. Elevated levels occur in acute and chronic pancreatitis, chronic renal failure and gastrointestinal malignancy [8,9], but among trauma patients, levels of PSP rise when sepsis develops [10]. High PSP levels at the onset of ventilator-associated pneumonia and in patients with septic shock predict mortality [11,12].…”

Section: Introductionmentioning

confidence: 99%

Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care

et al. 2013

View full text Add to dashboard Cite

IntroductionAlthough many sepsis biomarkers have shown promise in selected patient groups, only C-reactive protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three promising novel sepsis biomarkers in unselected patients at admission to intensive care. We assessed the performance of pancreatic stone protein (PSP), soluble CD25 (sCD25) and heparin binding protein (HBP) in distinguishing patients with sepsis from those with a non-infective systemic inflammatory response and the ability of these markers to indicate severity of illness.MethodsPlasma levels of the biomarkers, PCT and selected inflammatory cytokines were measured in samples taken from 219 patients during the first six hours of admission to intensive or high dependency care. Patients with a systemic inflammatory response were categorized as having sepsis or a non-infective aetiology, with or without markers of severity, using standard diagnostic criteria.ResultsBoth PSP and sCD25 performed well as biomarkers of sepsis irrespective of severity of illness. For both markers the area under the receiver operating curve (AUC) was greater than 0.9; PSP 0.927 (0.887 to 0.968) and sCD25 0.902 (0.854 to 0.949). Procalcitonin and IL6 also performed well as markers of sepsis whilst in this intensive care unit (ICU) population, HBP did not: PCT 0.840 (0.778 to 0.901), IL6 0.805 (0.739 to 0.870) and HBP 0.607 (0.519 to 0.694). Levels of both PSP and PCT reflected severity of illness and both markers performed well in differentiating patients with severe sepsis from severely ill patients with a non-infective systemic inflammatory response: AUCs 0.955 (0.909 to 1) and 0.837 (0.732 to 0.941) respectively. Although levels of sCD25 did not correlate with severity, the addition of sCD25 to either PCT or PSP in a multivariate model improved the diagnostic accuracy of either marker alone.ConclusionsPSP and sCD25 perform well as sepsis biomarkers in patients with suspected sepsis at the time of admission to intensive or high dependency care. These markers warrant further assessment of their prognostic value. Whereas previously published data indicate HBP has clinical utility in the emergency department, it did not perform well in an intensive-care population.

show abstract

“…CA19.9 is a glycoprotein expressed by several epithelial cancers, as well as in normal pancreatic and biliary duct epithelia, and it is used currently in the diagnosis and followup of gastrointestinal tumours [ 1 , 2 ]. High levels of CA19.9 have been observed in patients with gastric adenocarcinoma, in colon, biliary duct, and pancreatic carcinomas [ 3 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Carbohydrate 19.9 Antigen Serum Levels in Liver Disease

Bertino

Ardiri

Calvagno

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Background. Carbohydrate 19.9 antigen (CA19.9) has been used in the diagnosis and followup of gastrointestinal tumours. The aim of this prospective longitudinal study was the evaluation of CA19.9 levels in patients with chronic hepatitis and hepatic cirrhosis hepatitis C virus and B virus correlated. Materials and Methods. 180 patients were enrolled, 116 with HCV-related chronic liver disease (48% chronic hepatitis, 52% cirrhosis) and 64 with HBV-related chronic liver disease (86% chronic hepatitis, 14% cirrhosis). Patients with high levels of CA19.9 underwent abdominal ecography, gastroendoscopy, colonoscopy, and abdominal CT scan. Results. 51.7% of patients with HCV-related chronic liver disease and 48.4% of those with HBV-related chronic liver disease presented high levels of CA19.9. None was affected by pancreatic or intestinal neoplasia, cholestatic jaundice, or other diseases potentially able to induce Ca19.9 elevations. CA19.9 levels were elevated in 43.3% of HCV chronic hepatitis, in 56.3% of HCV cirrhosis, in 45.1% of HBV chronic hepatitis, and in 58% of HBV cirrhosis. Conclusions. CA19.9 commonly increases in the serum of patients with chronic viral hepatitis. Elevation of CA 19.9 is not specific for neoplastic disease and is related to the severity of fibrosis and to the viral aetiology of hepatitis.

show abstract

Untitled

Cited by 18 publications

References 15 publications

REG3β modifies cell tumor function by impairing extracellular vesicle uptake

REG3β modifies cell tumor function by impairing extracellular vesicle uptake

Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care

Carbohydrate 19.9 Antigen Serum Levels in Liver Disease

Contact Info

Product

Resources

About